A genetically modified strain of E. coli bacteria, designed to produce a specific protein, reduces tumor formation by half to two-thirds in mice with intestinal inflammation and a genetic predisposition to colon cancer, when given alongside a cancer-promoting bacterial strain.

Engineered bacteria with ClbS protein on their surface reduce DNA damage caused by a bacterial toxin in human colon tissue models and colorectal cancer cells.

A genetically modified strain of E. coli, designed to produce a protein that neutralizes colibactin, significantly lowers the levels of a harmful E. coli strain in the intestines of mice.

A genetically modified strain of E. coli bacteria, designed to display a specific protein, reduces signs of intestinal damage and inflammation in mice with chemically induced colitis, as shown by improved tissue scores and increased mucus-producing cells.

Certain strains of E. coli that produce colibactin are linked to distinct patterns of DNA damage found in colorectal tumors, particularly in younger patients, and these damage patterns are found in a portion of the mutations that drive tumor development.

Colorectal cancers with colibactin-related DNA damage patterns show the same levels of overall mutations and known cancer-causing gene changes as other colorectal cancers, suggesting colibactin causes cancer through a different biological mechanism.